Announcement PDF ASX Announcement 30/03/2021 Emyria and Cann Group Investor Webinar Emyria Limited (ASX: EMD) and Cann Group Limited (ASX: CAN) are pleased to invite shareholders to an Investor Briefing to be held on Thursday 1 April at 11:00 am AEDT Emyria’s Managing Director, Dr, Michael Winlo and Cann Group’s COO, Shane Duncan will discuss the recently announced collaboration agreement to seek accelerated registration of a unique, low-dose, CBD-only capsule with Australia’s Therapeutic Goods Administration (TGA). Details of the event are as follows: Event: Emyria and Cann Group Investor Webinar Webinar Presenters: Emyria’s Managing Director, Dr Michael Winlo and Cann Group’s COO, Shane Duncan Date and Time: Thursday 1 April 2021, 11:00 am AEDT Where: Zoom Webinar - details to be provided upon registration To register your interest in the webinar please click through to the link below. Registration Link: https://janemorganmanagement-au.zoom.us/webinar/register/WN_Oh8kr_YWT0 W3m0R12NzJew After registering your interest, you will receive a confirmation email with information about joining the webinar. Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to Lexi O’Halloran at lexi@janemorganmanagement.com.au Highlights (Refer to ASX Release 29 March 2021) ● Collaboration agreement aims to accelerate the registration of a Schedule 3, over-the-counter, cannabidiol (CBD) medicine in Australia ● Emyria’s EMD-003 drug development program will incorporate Cann Group’s newly acquired GelpellTM microsphere formulation technology ● Partnership provides potential significant cost and speed advantages to registration ● Successful registration with the Australian Therapeutic Goods Administration (TGA) opens the path to registration opportunities overseas ● Emyria and Cann Group will negotiate product commercialisation arrangements prior to a regulatory approval application being submitted This announcement has been approved and authorised for release by the Managing Director of Emyria Limited and the Company Secretary of Cann Group Limited. 1 For further information on Emyria: Dr Michael Winlo Managing Director (08) 6559 2800 mwinlo@emyria.com Lexi O’Halloran Media/Investor Relations + 61 (0) 404 577 076 lexi@janemorganmanagement.com.au Andrew Williams Media Relations +61 (0) 412 614 125 andreww@profilemedia.com.au For all media enquiries to Cann Group please contact: Matthew Wright NWR Communications +61 451 896 420 matt@nwrcommunications.com.au For all other information regarding Cann Group please contact: Peter Crock CEO Cann Group Limited +61 3 9095 7088 contact@canngrouplimited.com Clive Fanning Head of Investor Relations Cann Group Limited +61 3 9095 7088 contact@canngrouplimited.com Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. 2 About Emyria (www.emyria.com) Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au) Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs. Emyria’s first drug development program, EMD-003 is targeting unmet needs in mental health. Specifically psychological distress and the symptoms of anxiety, depression and stress. About Cann Group Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. Learn more at: www.canngrouplimited.com | www.satipharm.com 3